SLC2A1 and neoplasm: Overall, AGER, PECAM1, and SLC2A1 were validated for their expression in normal and LUAD tumor IHC samples, showing that the candidate gene biomarkers can function as biologically significant biomarkers to aid in the detection of early-stage LUAD.